Background: Accurate risk assessment for carcinogens requires an understanding of the link between the presence of the chemical in human tissues and the resulting biological effects of the exposure. Sensitive techniques are needed to measure the phenotypic effects of exposure and for studying genetic changes that may be directly in the pathway of the disease process. In addition, discovery of new genes in environmental response pathways and new polymorphisms in these response pathways has become an important focus. Previously we have developed quantitative methods to detect exposure-induced expression of CYP1A1, CYP1A2, UGT1, PAI2, and TGFa, and the oncogenic translocation in Bcl-2 t(14;18).
Aims : Develop technology and capacity for: 1) measuring exposure-induced expression 2) detecting germline polymorphism (oligoligation assay) 3) discovery of polymorphism Accomplishments: 1) Following our discovery and cloning of the rat TCDD-induced gene (25-Dx, a putative membrane bound progesterone receptor also known as mPr) collaborations were initiated to characterize the expression and function of the gene. In collaboration with M. Eddy, the mouse gene has been cloned and appears to be widely expressed during spermatogenesis. 2) Using our recently developed oligo ligation-based ELISA assay (OLA) for NAT1 polymorphisms, R. Boissy has analyzed ~3000 samples, producing for ~ 9,000 genotypes. This work will contribute to an estimated 5 manuscripts with the 1st paper in press (1) and a detailed methods manuscript being prepared. 3) Automated sample handling equipment and high throughput genotyping procedures were incorporated into the sample preparation and genotype analysis. Inventory and sample tracking systems are also being implemented. Significance: Development of these biomarker techniques will allow us to test hypotheses concerning the role of environmental and genetic factors in understanding the etiology of human disease.

National Institute of Health (NIH)
National Institute of Environmental Health Sciences (NIEHS)
Intramural Research (Z01)
Project #
Application #
Study Section
Special Emphasis Panel (LCBR)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
United States
Zip Code
Liu, Xuemei; Campbell, Michelle R; Pittman, Gary S et al. (2005) Expression-based discovery of variation in the human glutathione S-transferase M3 promoter and functional analysis in a glioma cell line using allele-specific chromatin immunoprecipitation. Cancer Res 65:99-104
Wang, Xuting; Tomso, Daniel J; Liu, Xuemei et al. (2005) Single nucleotide polymorphism in transcriptional regulatory regions and expression of environmentally responsive genes. Toxicol Appl Pharmacol 207:84-90
Lee, Su-Jun; Bell, Douglas A; Coulter, Sherry J et al. (2005) Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. J Pharmacol Exp Ther 313:302-9
Grant, Delores J; Hall, Ingrid J; Eastmond, David A et al. (2004) Bilirubin UDP-glucuronosyltransferase 1A1 (UGT1A1) gene promoter polymorphisms and HPRT, glycophorin A, and micronuclei mutant frequencies in human blood. Mutat Res 560:1-10
Mammen, Jennifer S; Pittman, Gary S; Li, Ying et al. (2003) Single amino acid mutations, but not common polymorphisms, decrease the activity of CYP1B1 against (-)benzo[a]pyrene-7R-trans-7,8-dihydrodiol. Carcinogenesis 24:1247-55
Fritsche, E; Baek, S J; King, L M et al. (2001) Functional characterization of cyclooxygenase-2 polymorphisms. J Pharmacol Exp Ther 299:468-76
Grant, D J; Bell, D A (2000) Bilirubin UDP-glucuronosyltransferase 1A1 gene polymorphisms: susceptibility to oxidative damage and cancer? Mol Carcinog 29:198-204